Kiniksa Pharmaceuticals International, plc (KNSA)

Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$93.89+0.38%As of 2026-11-22 · USD
Last session low $92.68Last session high $95.29
52-week low $37.0252-week high $99.31
Market cap
$7.38B
Sector
Healthcare
P/E (TTM)
71.1x

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)56.3In the neutral range (30 to 70)
MACD (12, 26, 9)3.28Below its signal line (3.83); histogram -0.55
Bollinger %B (20, 2)53%Inside the bands (82.65 to 103.74)
SMA 2093.19Price is 0.8% above
SMA 5083.90Price is 11.9% above
SMA 20064.09Price is 46.5% above
ATR (20)4.24% of priceAverage true range per day
52-week position91%In the upper part of the 37.02 to 99.31 range

About Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.

Latest fiscal yearEnded 2025-12-31: revenue of $677.56M and an operating margin of 11.4%.

More in Drug Manufacturers - Specialty & Generic